Evidence map›Paper›PMID 35042059›Full record

ReviewJournal of infection and public health2022

The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.

Jonaid Ahmad Malik, Sakeel Ahmed, Aroosa Mir, Mrunal Shinde, Onur Bender, Farhan Alshammari, Mukhtar Ansari, Sirajudheen Anwar

Open access · goldAbstract readReview
In one paragraph

Review in Journal of infection and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 3 pooled it
21.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 3 syntheses or guidelines pooled it, 208 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Potency ofThe Kobe journal of medical sciences · 2026
    Article
  12. On the role of dcm and vsr in Escherichia coli adaptive mutation.Molecular genetics and genomics : MGG · 2025
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Jonaid Ahmad MalikDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Guwahati, India; Department of Biomedical Engineering, Indian Institute of Technology (IIT), Ropar 140001, India.
Sakeel AhmedDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Ahmedabad, India.
Aroosa MirDepartment of Pharmacology, Jamia Hamdard, New Delhi, India.
Mrunal ShindeDepartment of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, India.
Onur BenderBiotechnology Institute, Ankara University, Ankara, Turkey.
Farhan AlshammariDepartment of Pharmaceutics, College of Pharmacy, University of Hail, Hail, Saudi Arabia.
Mukhtar AnsariDepartment of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia.
Sirajudheen AnwarDepartment of Pharmacology & Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia. Electronic address: si.anwar@uoh.edu.sa.
University of Ha'il · SAAnkara University · TRIndian Institute of Technology Ropar · INJamia Hamdard · INNational Institute of Pharmaceutical Education and Research · INNational Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe SARS-CoV-2 coronavirus epidemic is hastening the discovery of the most efficient vaccines. The development of cost-effective vaccines seems to be the only solution to terminate this pandemic. However, the vaccines' effectiveness has been questioned due to recurrent mutations in the SARS-CoV-2 genome. Most of the mutations are associated with the spike protein, a vital target for several marketed vaccines. Many countries were highly affected by the 2nd wave of the SARS-CoV-2, like the UK, India, Brazil and France. Experts are also alarming the further COVID-19 wave with the emergence of Omicron, which is highly affecting the South African populations. This review encompasses the detailed description of all vaccine candidates and COVID-19 mutants that will add value to design further studies to combat the COVID-19 pandemic.

methodsThe information was generated using various search engines like google scholar, PubMed, clinicaltrial.gov.in, WHO database, ScienceDirect, and news portals by using keywords SARS-CoV-2 mutants, COVID-19 vaccines, efficacy of SARS-CoV-2 vaccines, COVID-19 waves.

resultsThis review has highlighted the evolution of SARS-CoV-2 variants and the vaccine efficacy. Currently, various vaccine candidates are undergoing several phases of development. Their efficacy still needs to check for newly emerged variants. We have focused on the evolution, multiple mutants, waves of the SARS-CoV-2, and different marketed vaccines undergoing various clinical trials and the design of the trials to determine vaccine efficacy.

conclusionVarious mutants of SARS-CoV-2 arrived, mainly concerned with the spike protein, a key component to design the vaccine candidates. Various vaccines are undergoing clinical trial and show impressive results, but their efficacy still needs to be checked in different SARS-CoV-2 mutants. We discussed all mutants of SARS-CoV-2 and the vaccine's efficacy against them. The safety concern of these vaccines is also discussed. It is important to understand how coronavirus gets mutated to design better new vaccines, providing long-term protection and neutralizing broad mutant variants. A proper study approach also needs to be considered while designing the vaccine efficacy trials, which further improved the study outcomes. Taking preventive measures to protect from the virus is also equally important, like vaccine development.

Indexed as

COVID-19VaccinesCOVID-19 VaccinesHumansMutationPandemicsSARS-CoV-2COVID-19 VaccinesVaccinesClinical trialsCovid-19MutationsVaccine efficacyVariant strains

Identifiers

PMID35042059
PMCPMC8730674
OpenAlexW4206405158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.